Background. Postdiarrheal hemolytic-uremic syndrome (D+HUS) following Shiga toxin-producing Escherichia coli (STEC) infection is a serious condition lacking specific treatment. Host immune dysregulation and genetic susceptibility to complement hyperactivation are implicated in non-STEC-related HUS. However, genetic susceptibility to D+HUS remains largely uncharacterized.
factor H (CFH), leading to altered or persistent complement activation [7, 11] . Host genetic factors predisposing to D+HUS remain uncharacterized, however, in large part because of the logistical challenges of orchestrating epidemiologic studies in the midst of infectious disease outbreaks. The outbreak of foodborne STEC O104:H4 infections in Germany in 2011, associated with contaminated sprouts, resulted in a high incidence of D+HUS among adults and children, underscoring the need to better understand D+HUS pathogenesis and identify prognostic biomarkers and therapeutic targets [6, 12, 13] . Prompt diagnosis of O157 and other highly virulent STEC infections is critical; parenteral volume expansion early in the course of infection can limit renal damage and improve clinical outcomes [14, 15] . In addition, antibiotic therapy for STEC O157 infections has been associated with more-severe disease; early and accurate diagnosis therefore facilitates appropriate treatment [16, 17] . Identification of new pathophysiological mechanisms of D+HUS and development of multipronged adjunctive therapies targeted to these mechanisms could significantly reduce morbidity and mortality.
The objective of this case-control study was to identify host genetic factors that confer susceptibility to D+HUS following STEC infection and to assess the contribution of complement-regulatory gene mutations that have previously been identified as risk factors for atypical HUS.
PATIENTS AND METHODS

Ascertainment of Study Subjects
The Foodborne Diseases Active Surveillance Network (FoodNet) is a population-based surveillance network of 10 sites, encompassing 15% of the US population [18] . FoodNet conducts active, laboratory-based surveillance for 9 types of enteric bacterial infections, including O157 and non-O157 STEC. Individuals residing within the FoodNet catchment area during 2007-2012 who developed diarrheal illness and were determined to have laboratory-confirmed STEC-related diarrhea or clinician-diagnosed D+HUS were eligible for this study. STEC infection was confirmed by culture, enzyme-linked immunoassay for Shiga toxins, and/or polymerase chain reaction for genes encoding Shiga toxins. Additionally, serological evidence of STEC O157 and O111 infections was accepted for patients with D+HUS and no STEC isolated from their stool. Demographic and clinical information, such as race, renal function, and antimicrobial use, were obtained through a concurrent but separate FoodNet cohort study of the risks of D+HUS and antimicrobial exposure, which closed in 2010; samples for DNA extraction continued to be collected from cases ascertained via routine FoodNet surveillance but with more-limited clinical data. Study participants without clinical covariate data were excluded from the present analysis.
D+HUS was defined as confirmed if all 4 of the following laboratory abnormalities were met: (1) hemoglobin level or hematocrit below age-and sex-specific thresholds, (2) platelet count of <150 × 10 3 platelets/μL, (3) serum creatinine level of ≥1.0 mg/ dL if <13 years old or ≥1.5 mg/dL if ≥13 years old, and (4) fragmented erythrocytes on peripheral blood smear [19] . Probable cases met the first 3 criteria but lacked evidence of erythrocyte fragmentation. Physician-diagnosed cases without sufficient data for further classification were defined as suspected D+HUS. Cases were excluded if sufficient DNA could not be extracted, if they opted out of genetic testing, or if they spoke neither English nor Spanish. Controls comprised participants with documented STEC-related diarrhea who did not develop D+HUS as defined by any of the above criteria and who were similarly ascertained via FoodNet surveillance during the same period. STEC exposures were classified as O157:H7 or non-O157:H7, and only the former group was analyzed, to ensure that microbiologic risk was similar between study participants.
Written and verbal informed consent were obtained from participants aged ≥14 years; a parent or legal guardian provided written and verbal consent for patients aged <18 years. A waiver of assent was obtained for minors aged <14 years. The study was approved by the institutional review boards of Vanderbilt University, all participating state health departments, and the Centers for Disease Control and Prevention (CDC).
Gene Selection
For candidate-gene selection, we assumed that D+HUS pathogenesis overlaps that of atypical HUS and involves vascular injury as a final common pathway. In addition to including genes and single-nucleotide polymorphisms (SNPs) that have been associated with atypical HUS, SNPs associated with vascular endothelial injury via complement-or immune-mediated mechanisms and those involved in regulating inflammation, prostaglandin synthesis, vascular integrity, and endothelial-cell activation were identified in literature searches, using the following search terms: "genetic, " "risk, " "hemolytic-uremic syndrome, " "HUS, " "polymorphism, " "typical" (or "STEC, " or "post-diarrheal"), and "thrombotic thrombocytopenic purpura. " Since iron transport is fundamentally important in immune regulation and resistance to microbial infections via the hepcidin-ferroportin pathway [20] , genes encoding iron transport-related proteins were also included. The National Institutes of Health Genetic Association Database (2004-2014; available at: http://geneticassociationdb. nih.gov/) was searched for genetic variants associated with arteriovascular or renal injury, microvascular thrombosis, and renal failure [20] . Finally, candidate SNPs were searched in the SNPedia database (available at: http://www.snpedia.com/index. php/SNPedia) for additional confirmation of phenotype associations, when possible. Representative candidate genes and chromosomal loci evaluated in this study and their known disease associations are listed in Table 1. A list of the 78 genes and all  SNPs evaluated is provided in Supplementary Table 1 .
Laboratory and DNA Methods
Either mouthwash (oral rinse) or buccal swab kits (Oragene) were used to collect buccal cell samples. Whole-genome DNA amplification was performed on 226 samples that were collected using the mouthwash protocol to obtain adequate DNA for genetic analysis. Genomic DNA was extracted using PureGene (Gentra Systems, Minneapolis, MN). Genotyping was performed (blinded to clinical outcome) by Sequenom assay or custom ABI TaqMan assay (ABI Prism 7900 HT Sequence Detection System, Applied Biosystems, Foster City, CA), based on the variant. Proprietary probe and primer sequences, cycling, and scanning conditions for customized TaqMan assays are available from the manufacturer upon request. Genetic data were analyzed using ABI Sequence Detection Software v2.1 software, and calls were confirmed by visual inspection of plots.
Statistical Methods
Comparison of baseline characteristics was performed using the Wilcoxon rank sum test for nonnormally distributed, continuous variables (ie, age), and either the χ 2 test or Fisher's exact test was used for categorical variables (eg, sex, race, and antibiotic use). Genetic associations were evaluated by multivariable logistic regression, with adjustment for age at diagnosis, sex, race (non-Hispanic white vs other races), and antibiotic use within 7 days of diarrhea onset and before D+HUS diagnosis (yes vs no), and the need for whole-genome amplification (yes vs no). Three D+HUS outcomes were considered: (1) individuals who fulfilled criteria for confirmed, probable, or suspected D+HUS (outcome 1); (2) probable or confirmed cases only (outcome 2); and (3) confirmed cases only (outcome 3). The referent group for analyses of all 3 D+HUS outcomes included only individuals who did not fulfill any HUS criteria. As stated above, the case-control analysis presented here was also restricted to individuals with known E. coli serotype O157:H7. An unbiased, additive genetic model was used for all analyses. Bonferroni corrections for multiple statistical tests were not used, owing to the exploratory nature of the analysis and small case sample size, to limit type II error. SAS statistical software v12.0 was used for all analyses; 2-sided P values of < .05 were considered statistically significant.
RESULTS
We identified 837 individuals with diarrheal illness or clinical symptoms suggestive of D+HUS, 818 of whom were eligible for this genetic study (Figure 1 ). Nine subjects had insufficient DNA for genetic testing or whole-genome amplification, 8 opted out of genetic testing or did not provide written consent, and 2 provided duplicate samples. After we excluded 52 samples with call rates of <90% for ≥1 SNP and 125 individuals with either unknown or non-O157 STEC serotypes, 641 subjects were evaluable, 80 of whom were classified as D+HUS cases; 561 were controls without evidence of HUS. Since 243 of these individuals had not been enrolled in the separate STEC cohort study and therefore lacked sufficient laboratory data for further classification, 398 were available for unadjusted analyses involving more-stringent D+HUS case definitions; 12 additional individuals were excluded from multivariable analyses, because of incomplete or absent covariate data. Of 80 cases with suspected D+HUS, 41 had probable D+HUS, and 32 had confirmed D+HUS.
D+HUS cases were significantly younger than controls (median age, 7 vs 21 years). Participants were predominantly non-Hispanic white by self-report (Table 2) . A nonsignificantly higher proportion of cases was female. The proportion of samples from individuals without HUS that required DNA amplification (44%) was higher than the proportion of samples from suspected, probable, and confirmed D+HUS cases that required amplification (37%, 33%, and 34%, respectively; P < .01 for comparison across groups).
Unadjusted Genetic Analyses
To ensure as much uniformity of microbiologic risk as possible across STEC-exposed individuals, we restricted our analyses to subjects with documented STEC serotype O157:H7, comprising 80 suspected D+HUS cases and 561 controls. Results of unadjusted analyses of SNP associations with D+HUS are shown in Table 3 . Significant associations with at least 1 D+HUS definition were observed for 16 evaluated SNPs, encompassing 5 gene categories: (1) . Two SNPs, rs20417 in PTGS2 and rs4986791 in TLR4, were associated with an increased likelihood of all D+HUS outcomes, with odds ratios (ORs) of 1.8-2.7. PTGS2 rs20417 associations with outcomes 2 and 3 (P < .01 for both) were also stronger than that with outcome 1 and met gene-based Bonferroni criteria for significance (P < 6 × 10 -4 ). Of note, point estimates of the ORs for association were in the same direction for all D+HUS outcome definitions for all but 1 SNP.
Adjusted Genetic Analyses
Results of analyses of selected SNPs in 386 patients, adjusted for age, sex, race, antibiotic use within 1 week of symptom onset, and DNA amplification, are shown in Table 4 . Manhattan plots for each D+HUS outcome definition are shown in Figure 2A -C. These analyses identified SNPs in 11 different genes and 1 intergenic SNP that were associated with ≥1 D+HUS outcome definitions.
Two variants were significantly associated only with confirmed D+HUS (outcome 3): C4BPA rs9943077 and IL6R rs8192284 (adjusted ORs, 0.47 and 1.75, respectively). These ORs indicate a decreased D+HUS risk associated with SNP rs9943077 and an increased risk associated with SNP rs8192284.
In 5 genes, SNPs were significantly associated with all 3 D+HUS outcome definitions: an intergenic SNP (rs10874639) nearest the collagen XI gene COL11A1, rs3804141 in TFRC, rs5370 in EDN1, rs121908064 in GP1BA, and rs16966334 in B2M. Subjects with D+HUS were more likely to have rs10874639_G (range of adjusted ORs, 2.2-2.6), TFRC rs3804141_A (range of adjusted ORs across case definitions, 2.4-2.9), GP1BA rs121908064_A (range of adjusted ORs, 13.3-27.4), and B2M rs16966334_G alleles (range of adjusted ORs, 4.2-5.4). In contrast, D+HUS cases were less likely to have the EDN1 rs5370_T allele (range of adjusted ORs, 0.34-0.48).
Associations were observed for SNPs rs4986791 in TLR4 and rs4792847 in MAP3K14 (a tumor necrosis factor α receptor [TNFR] superfamily gene) for an increased and decreased risk of 2 D+HUS outcomes (1 and 2), respectively. Both of these SNPs also showed borderline associations with outcome 3 (confirmed HUS; P < .075 for both); the TLR4 SNP, which was significant in unadjusted analyses, retained borderline significance after adjustment. Three SNPs, CFHR1-5 rs6677604, rs315951 in IL1RN, and rs2234649 in TNFR1, were each associated with 1 D+HUS outcome definition (P ≤ .05 for all); one of these SNPs (rs315951_C) conferred a decreased risk. The CFHR1-5 variant also showed a borderline association with outcome 1 (ie, suspected D+HUS; P = .06). All but 2 individuals were non-Hispanic white; hence, adjusted ORs in analyses restricted to non-Hispanic whites for all D+HUS outcomes (1, 2, and 3) yielded very similar results (data not shown). 
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Nine SNPs identified in unadjusted analyses, PTGS1 rs883484, PTGS2 rs20417, C4BPA rs11120211, TFRC rs4927866 and rs480760, TLR3 rs3775291, SLC11A2 rs224572, BMP2 rs1979855, and ADAMTS13 rs652600, lost significance following adjustment, although 6 of these retained a borderline statistically significant association with at least 1 D+HUS outcome. Genetic variants associated with D+HUS with adjusted P values of >.05 and ≤.15 are listed in Supplementary Table 2 . Borderline associations for 2 of these SNPs, rs7673587 in the fibrinogen β chain gene FGB and rs1801133 in MTHFR, were observed with all 3 D+HUS outcomes.
DISCUSSION
Ever since the 1918 influenza pandemic, public health clinicians have documented unpredictable morbidity and mortality in previously healthy individuals, triggered by an excessive inflammatory response [22] [23] [24] . Uncharacterized host factors may confer susceptibility to these life-threatening complications [17, 23, [25] [26] [27] . This exploratory study was designed to cast the net wide for host genetic factors that predispose to D+HUS following STEC exposure [6] . Furthermore, multistate FoodNet consortium resources greatly facilitated identification of carefully ascertained D+HUS cases and controls. Detailed ascertainment of likely cofactors in D+HUS development, such as antibiotic use during the first week of STECrelated diarrheal illness, was imperative to account for possible confounding in multivariable-adjusted analyses. Based on a candidate-gene list derived from published reports linking host genetic factors to renal and vascular injury and atypical HUS, this study identified many biologically plausible associations and is the first of its kind.
Several genes (TFRC, EDN1, GP1BA, and B2M), as well as an intergenic SNP nearest COL11A1, showed significant associations with all levels of D+HUS. Variants in TFRC, which encodes a critical cellular iron transporter, predispose to severe diarrhea after STEC infection in livestock, albeit by an unknown mechanism [28] . EDN1 variants have been associated with several vascular phenotypes, including a reduced risk of diabetic retinopathy [29] . GP1BA encodes a platelet membrane glycoprotein, which functions as a receptor for von Willebrand factor and in platelet adhesion to the vascular endothelium after intravascular injury. GP1BA complexes with other proteins involved in platelet signaling, enhancing platelet activation [30] . Thrombocytopenia, a well-recognized clinical feature of HUS, results from thrombotic microangiopathy and platelet consumption and is a key component of HUS pathophysiology [9] . Similarly, B2M encodes the serum protein β-2-microglobulin, which is required for normal cell-surface expression of other major histocompatibility complex class I proteins and is widely expressed [31] . Urinary β-2-microglobulin levels have been reported to rise precipitously preceding the onset of azotemia, thrombocytopenia, and renal failure in children with HUS [32, 33] . It is particularly noteworthy that, for many significant SNPs in this study, such as SNPs in GP1BA, B2M, EDN1, and TFRC and the intergenic SNP, the magnitude of estimated associations increased progressively with the stringency D+HUS definition or were undiminished when the most stringent case definition was used, despite smaller case numbers. A role for complement is established in atypical HUS pathophysiology, and borderline associations identified here between suspected, probable, and/or confirmed D+HUS and SNPs in CFHR1-5 and intronic SNP rs9943077 in C4BPA suggest a similar but possibly less prominent role for complement in D+HUS. CFHR1-5 SNPs rs667604 and 16840639 have both been associated with systemic lupus erythematosus, an autoimmune disease characterized by complement hyperactivation [34] . Involvement of complement-related genes in D+HUS may explain anecdotal reports of clinical improvement in STEC-related D+HUS after treatment with eculizumab, a recombinant inhibitor of terminal complement (C5) [35] . However, these observations are based on small case series that lacked comparison groups, and reports of efficacy are inconsistent, supporting the contention that other host factors contribute to D+HUS pathogenesis [17] . If associations of PTGS2 (COX2) SNP rs20417, which is associated with impaired aspirin sensitivity, and SNPs in GP1BA and IL1RN are replicated and/or strengthened in larger studies, higher-dose COX-2 inhibitors or other antiplatelet agents, as well as recombinant IL-1R antagonists, may be beneficial in preventing D+HUS in individuals with these variants. IL1RN encodes an IL-1R ligand, which inhibits IL-1 signaling; IL1RN variants have been associated with microvascular complications of diabetes mellitus and with immunoglobulin A nephropathy [36] [37] [38] . Since D+HUS similarly involves microvascular injury, prior associations of IL1RN and PTGS2 with other vascular pathologies argue for further exploration of these SNPs in D+HUS. Recent investigation of in vitro metabolic effects of Shiga toxins in human endothelial cells strongly implicated the eicosanoid pathway, which involves PTGS2-mediated prostaglandin synthesis, lending further validity to our finding of a possible association of PTGS2 rs20147 with this phenotype [39] . It is also noteworthy that 4 genes related to iron metabolism were identified (TFRC, B2M, and more-borderline associations with BMP2 and SLC11A2/ DMT1). Finally, an intergenic SNP, rs10874639, which resides in a protein quantitative trait locus and has been associated with fibrinogen levels, was associated with all levels of D+HUS in our study [40] . Fibrinogen is an important component of the final common pathway of coagulation.
This study was clearly limited by the modest number of D+HUS cases (despite an intensive, multistate ascertainment effort), the lack of STEC genotype data, and the absence of associations that retained significance after correction for multiple statistical tests. To balance type I and type II error, a list of SNPs of lesser significance was also generated for future investigation. We used both rigorous and flexible case definitions, deliberately exchanging some statistical power for diagnostic precision. The suspected, probable, or confirmed HUS outcome (outcome 1) is particularly prone to misclassification; hence, the most attention should be given to associations with confirmed D+HUS (outcome 3), followed by confirmed or probable D+HUS (outcome 2). Because the study population predominantly comprised non-Hispanic white individuals, it was unfortunately not possible to evaluate genetic variants that confer susceptibility to D+HUS in minority populations. We were, however, mindful of the possibility of selection bias and sought to minimize it by using a population-based, prospective enrollment strategy within the FoodNet catchment area. Although we cannot exclude the possibility of genetic relatedness in our sample, we believe the likelihood of this to be small. Cases were also considerably younger than controls, but age-matching was not performed, to retain as many individuals in the analysis as possible to optimize power. However, all multivariable models were age-adjusted, and none of the SNPs we evaluated is known to be associated with age. Nevertheless, we cannot completely exclude the possibility of residual confounding by age.
In conclusion, this study implicates variants in several noncomplement-related genes (including those involved in iron transport, cytokine signaling, platelet function, pathogen recognition, and endothelial function) and, possibly, in genes encoding complement-pathway proteins, in the development of D+HUS, suggesting previously unrecognized host susceptibility factors in this serious complication of STEC infection. STEC infections and outbreaks will inevitably still occur, and this relatively unique study suggests that genetic testing might be efficiently performed on STEC-exposed individuals at risk of D+HUS using a customized SNP panel. Targeted genotyping of STEC-exposed individuals for the identified variants, reducing the multiple-testing burden, are needed to validate these findings; if the findings are replicated, therapeutic interventions focusing on these pathways may warrant concurrent investigation at the bench and at the bedside.
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